您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > ACS 67
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
ACS 67
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
ACS 67图片
CAS NO:1088434-86-9
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
25mg电议

产品介绍

化学性质

Physical AppearanceA crystalline solid
StorageStore at -20°C
M.Wt598.8
Cas No.1088434-86-9
FormulaC32H38O5S3
Solubility≤2mg/ml in ethanol;20mg/ml in DMSO;30mg/ml in dimethyl formamide
Chemical Name7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl ester, 5Z-heptenoic acid
Canonical SMILESO[C@@H]1[C@H](C/C=C\CCCC(OC2=CC=C(C3=CC(SS3)=S)C=C2)=O)[C@@H](CC[C@@H](O)CCC4=CC=CC=C4)[C@H](O)C1
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

ACS 67 is an analog of latanoprost acid.

Latanoprost, an F-series prostaglandin (PG) analog, has been approved for use as an ocular hypotensive drug for the treatment of glaucoma clinically. Latanoprost is an isopropyl ester, a prodrug form which is converted to free latanoprost acid by endogenous esterase enzymes.

In vitro: In previous study, ACS 67 was found to be able to increase the reduced glutathione levels in normotensive pigmented rabbits significantly after single administration in a dose-dependent manner. Furthermore, in glaucomatous pigmented rabbits after repeated 5-day administration, ACS 67 could also increase the GSH levels when compared with latanoprost. In addition, it was found that ACS 67 could significantly increase the cGMP levels in glaucomatous pigmented rabbits and these data with the combination supported that the increase of cGMP was due to the sulfurated moiety of ACS 67. Moreover, the tolerability was measured in New Zealand albino rabbits at three different concentrations of ACS 67, and results indicated that ACS 67 was very well tolerated in Draize test [1].

In vivo: So far, there in no animal in vivo data reported.

Clinical trial: Up to now, ACS 67 is still in the preclinical development stage.

Reference:
[1] E.  Perrino, C. Uliva, C. Lanzi, et al. New prostaglandin derivative for glaucoma treatment. Bioorganic & Medicinal Chemistry Letters 19, 1639-1642 (2009).